惠迪联合双歧四联活菌治疗肠易激综合征疗效观察

Clinical observation on the combination of Huidi mesalazine and Bifid Tetragenous Viable Bacteria Tablets to treat patients for irritable bowel syndrome

目的探讨惠迪联合双岐四联活菌治疗肠易激综合征(IBS)的临床疗效。方法 92例肠易激综合征患者随机分成两组:46例患者纳入对照组,单独服用惠迪;46例患者纳入治疗组,联合服用惠迪和双岐四联活菌片。观察治疗前后的体征和各种症状的情况,同时观察治疗期间药物引发的不良反应发生情况。结果治疗组的总有效率是93.4%,对照组的总有效率是73.9%。两组之间差异有统计学意义(P<0.05)。两组均未见不良反应发生。结论惠迪联合双岐四联活菌治疗肠易激综合征临床疗效明显,具有推广价值。

Objective To observe the clinical effects of the combination of Huidi mesalazine and Bifid Tetragenous Viable Bacteria Tablets in treating patients for irritable bowel syndrome（IBS）.Methods 92 patients were randomly divided into two groups：control group contains 46 patients.All patients were only treated with Huidi mesalazine;treated group contains 46 patients.All patients were treated Huidi mesalazine and Bifid Tetragenous Viable Bacteria Tablets.The all kinds of symptoms were observed,before and after treatment.At the same time,the drug-induced adverse events were observed.Results The total effective rate in treated group was 93.4% while that in control group was 73.9%.The difference was markedly obvious（P0.05）.Conclusion The treatment of the combination of Huidi mesalazine and Bifid Tetragenous Viable Bacteria Tablets for irritable bowel syndrome has markedly effect,and it is worthy of promotion.